Addressing Risk Assessment and Early Detection of Cancer

The potential of blood tests for multi-cancer early detection (MCED) to reduce cancer mortality has elicited substantial interest. However, it is unlikely that in the foreseeable future such tests would replace currently available cancer screening programs. Thus, an important need for these common cancers is for biomarker tests that, in combination with subject characteristics, would improve the efficiency of screening by providing personalized screening schedules to individuals based on their risk. For other less common cancers for which screening in a general population setting is not practical, blood based tests would identify individuals at sufficiently high risk to be screened for these cancers.